UB-941 is a selective Raf kinase inhibitor against Raf, B-Raf (V600E), and C-Raf with IC50 < 5 nM. UB-941 is selectively toxic to B-Raf mutant positive cancer cells and effectively inhibits the RAF signaling pathway, and exhibits good pharmacokinetic properties and oral bioavailability. Orally administration of UB-941 alone effectively suppresses the tumor growth in B-Raf mutant positive melanoma and colon cancer xenograft model. The overall drug potencies and safety are better than the benchmark Vemurafenib and Dabrafenib. At present, UB-941 has obtained IND approval in US and Taiwan, and the patent regarding chemical structure has also been granted in multiple nations.

A highly active and specific oral RAF kinase inhibitor, the overall drug potencies and safety are better than the benchmark Vemurafenib and Dabrafenib, demonstrating the competitiveness and drug development value.